Neurochase
Neurochase is dedicated to developing innovative CNS drug delivery systems using state-of-the-art technology. Their mission is to bring transformative therapies to patients with neurological diseases through bespoke therapeutic strategies, focusing on safe, effective, and scalable delivery solutions for gene and other therapies. The company aims to address the challenges of delivering treatments to the central nervous system, improving clinical outcomes and enabling the next generation of CNS therapeutics.
Industries
Nr. of Employees
small (1-50)
Neurochase
Bristol Office: St. Brandon's House, 29 Great George St, Avon, Bristol, BS1 5QT
Products
Investigational convection-enhanced delivery device for intraparenchymal CNS infusion
An investigational catheter-based system designed for targeted, intraparenchymal infusion to deliver therapeutic agents directly to brain and spinal cord target structures with features for rapid implantation, precise targeting, reflux control and compatibility with stereotactic frames/robots.
Investigational convection-enhanced delivery device for intraparenchymal CNS infusion
An investigational catheter-based system designed for targeted, intraparenchymal infusion to deliver therapeutic agents directly to brain and spinal cord target structures with features for rapid implantation, precise targeting, reflux control and compatibility with stereotactic frames/robots.
Services
Advisory services for biotech and pharma on direct delivery of therapies to the central nervous system, including indication-specific delivery strategies.
Support for pre-clinical studies including protocol development, selection of equipment and devices to optimize drug distribution in target CNS structures.
Services covering clinical protocol development, surgical workflow optimisation and training for surgeons performing direct CNS delivery procedures; planned access to investigational CED devices to support clinical studies.
Advisory services for biotech and pharma on direct delivery of therapies to the central nervous system, including indication-specific delivery strategies.
Support for pre-clinical studies including protocol development, selection of equipment and devices to optimize drug distribution in target CNS structures.
Services covering clinical protocol development, surgical workflow optimisation and training for surgeons performing direct CNS delivery procedures; planned access to investigational CED devices to support clinical studies.
Expertise Areas
- Convection-enhanced CNS delivery
- Clinical trial protocol development for CNS therapies
- Surgical workflow optimisation and surgeon training
- Pre-clinical support for CNS delivery studies
Key Technologies
- Convection-enhanced delivery (CED)
- Electrospun microcatheters
- Micro-dissector probe design
- Stereotactic frames and robotic implantation
News & Updates
Neurochase will be a first-time exhibitor at the ASGCT 28th Annual Meeting, showcasing their advancements in CNS drug delivery.
Jacqueline Keller, industry veteran, joins Neurochase as the company prepares to bring its pioneering CNS drug delivery device to market.
VIVOLTA collaborates with Neurochase to manufacture electrospun micro-catheters for delivering advanced CNS therapies.
Spark Therapeutics collaborates with Neurochase to utilize proprietary delivery technology for CNS disorders.
Neurochase will be a first-time exhibitor at the ASGCT 28th Annual Meeting, showcasing their advancements in CNS drug delivery.
Jacqueline Keller, industry veteran, joins Neurochase as the company prepares to bring its pioneering CNS drug delivery device to market.
VIVOLTA collaborates with Neurochase to manufacture electrospun micro-catheters for delivering advanced CNS therapies.
Spark Therapeutics collaborates with Neurochase to utilize proprietary delivery technology for CNS disorders.